Your session is about to expire
← Back to Search
Corticosteroid
H.P. ACTHAR GEL for Vasculitis
Phase 4
Waitlist Available
Research Sponsored by Ocular Immunology and Uveitis Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day to 24 weeks
Awards & highlights
Study Summary
This trial will study the effects of Acthar on adults with a non-infectious form of eye inflammation.
Eligible Conditions
- Vasculitis
- Posterior Uveitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 day to 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day to 24 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of responders to Acthar at the end of treatment.
Secondary outcome measures
Percentage of patients requiring rescue therapy.
Presence or absence of active retinal vasculitis at all other time points.
Safety assessments, including drug tolerability and adverse events; other ocular and/or systemic complications.
Trial Design
1Treatment groups
Experimental Treatment
Group I: H.P. ACTHAR GELExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Ocular Immunology and Uveitis FoundationLead Sponsor
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger